Transbronchial cryobiopsy in fibrosing interstitial lung disease: modifications of the procedure lead to risk reduction

Thorax. 2019 Jul;74(7):711-714. doi: 10.1136/thoraxjnl-2018-212095. Epub 2019 Mar 9.

Abstract

Sixty-one subjects with fibrosing interstitial lung disease were prospectively analysed to determine the efficacy of transbronchial cryobiopsy (CryoTBB) and the effect of procedural modifications which were introduced after an interim analysis of the first 19 subjects. The modifications significantly reduced complication rates from 84% to 14% (p<0.001). 30-day-mortality was 2%. The algorithm with initial CryoTBB and surgical lung biopsy (SLB) as optional step-up procedure was feasible. CryoTBB led to a confident diagnosis in 46/61 subjects (75%). Only 21% out of all subjects were forwarded for SLB. As the modified CryoTBB reduced but not eliminated the risk of severe complications, tissue sampling should be limited to patients where confident diagnosis enables life prolonging therapy. Trial registration number: NCT01714518.

Keywords: bronchoscopy; hypersensitivity pneumonitis; idiopathic pulmonary fibrosis; interstitial fibrosis; thoracic surgery.

MeSH terms

  • Aged
  • Algorithms
  • Biopsy / adverse effects
  • Biopsy / methods
  • Cryosurgery / adverse effects
  • Cryosurgery / methods
  • Female
  • Humans
  • Lung / pathology*
  • Lung Diseases, Interstitial / diagnosis
  • Lung Diseases, Interstitial / pathology*
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Prospective Studies
  • Risk Reduction Behavior

Associated data

  • ClinicalTrials.gov/NCT01714518